TNF and venous thromboembolism: The results showed an increased risk of death, malignancy, major adverse cardiac events (MACE), and venous thromboembolism (VTE) in tofacitinib-treated patients (both 5mg and 10 mg arms) compared to those treated with TNF inhibitors (58).